Clinical Trial Design Feasibility Assessment

3. Feasibility Score (0-100)

Weighted composite score:

• Patient Availability (30%): Population size × biomarker prevalence × geography
• Endpoint Precedent (25%): Historical use, regulatory acceptance
• Regulatory Clarity (20%): Pathway defined, precedents exist
• Comparator Feasibility (15%): Standard of care availability
• Safety Monitoring (10%): Known risks, monitoring established

When to Use This Skill

Apply when users:

• Plan early-phase trials (Phase 1/2 emphasis)
• Need enrollment feasibility assessment
• Design biomarker-selected trials
• Evaluate endpoint strategies
• Assess regulatory pathways
• Compare trial design options
• Need safety monitoring plans

Trigger phrases: "clinical trial design", "trial feasibility", "enrollment projections", "endpoint selection", "trial planning", "Phase 1/2 design", "basket trial", "biomarker trial"

Quick Start

from tooluniverse import ToolUniverse

tu = ToolUniverse(use_cache=True)
tu.load_tools()

# Example: EGFR+ NSCLC trial feasibility
indication = "EGFR-mutant non-small cell lung cancer"
biomarker = "EGFR L858R"

# Step 1: Get disease prevalence
disease_info = tu.tools.OpenTargets_get_disease_id_description_by_name(
    diseaseName="non-small cell lung cancer"
)

prevalence = tu.tools.OpenTargets_get_diseases_phenotypes(
    efoId=disease_info['data']['id']
)

# Step 2: Estimate biomarker prevalence
# EGFR mutations: ~15% of NSCLC in US, ~50% in Asia
variants = tu.tools.ClinVar_search_variants(
    gene="EGFR",
    significance="pathogenic"
)

# Step 3: Find precedent trials
trials = tu.tools.search_clinical_trials(
    condition="EGFR positive non-small cell lung cancer",
    status="completed",
    phase="2"
)

# Step 4: Identify standard of care comparator
soc_drugs = tu.tools.FDA_OrangeBook_search_drugs(
    ingredient="osimertinib"  # Current SOC for EGFR+ NSCLC
)

# Compile into feasibility report...

Core Strategy: 6 Research Paths

Execute 6 parallel research dimensions:

Trial Design Query (e.g., "EGFR+ NSCLC trial, Phase 2, ORR endpoint")
│
├─ PATH 1: Patient Population Sizing
│   ├─ Disease prevalence (OpenTargets_get_diseases_phenotypes)
│   ├─ Biomarker prevalence (ClinVar, gnomAD, literature)
│   ├─ Geographic distribution (clinical trials, epidemiology)
│   ├─ Eligibility criteria impact (age, comorbidities)
│   └─ Patient availability calculator
│
├─ PATH 2: Biomarker Prevalence & Testing
│   ├─ Mutation frequency (ClinVar, COSMIC, gnomAD)
│   ├─ Testing availability (CLIA labs, FDA-approved tests)
│   ├─ Test turnaround time
│   ├─ Cost and reimbursement
│   └─ Alternative biomarkers (correlates, surrogates)
│
├─ PATH 3: Comparator Selection
│   ├─ Standard of care (FDA_OrangeBook, guidelines)
│   ├─ Approved comparators (DrugBank, FDA labels)
│   ├─ Historical controls feasibility
│   ├─ Placebo appropriateness
│   └─ Combination therapy considerations
│
├─ PATH 4: Endpoint Selection
│   ├─ Primary endpoint precedents (search_clinical_trials)
│   ├─ FDA acceptance history (FDA_get_approval_history)
│   ├─ Measurement feasibility (imaging, biomarkers)
│   ├─ Time to event considerations
│   └─ Surrogate vs clinical endpoints
│
├─ PATH 5: Safety Endpoints & Monitoring
│   ├─ Mechanism-based toxicity (drugbank_get_pharmacology)
│   ├─ Class effect toxicities (FAERS_search_reports)
│   ├─ Organ-specific monitoring (liver, cardiac, etc.)
│   ├─ Dose-limiting toxicity history
│   └─ Safety monitoring plan
│
└─ PATH 6: Regulatory Pathway
    ├─ Regulatory precedents (505(b)(1), 505(b)(2))
    ├─ Breakthrough therapy potential
    ├─ Orphan drug designation (if rare)
    ├─ Fast track eligibility
    └─ FDA guidance documents

Report Structure (14 Sections)

Create [INDICATION]_trial_feasibility_report.md with:

1. Executive Summary

# Clinical Trial Feasibility Report: [INDICATION]

**Date**: [YYYY-MM-DD]
**Trial Type**: [Phase 1/2, biomarker-selected, basket, etc.]
**Primary Endpoint**: [ORR, PFS, DLT, etc.]
**Feasibility Score**: [0-100] - [LOW/MODERATE/HIGH]

## Key Findings
- **Patient Availability**: [Est. enrollable patients/year in US]
- **Enrollment Timeline**: [Months to target N]
- **Endpoint Precedent**: [Grade A/B/C/D] - [Description]
- **Regulatory Pathway**: [505(b)(1), breakthrough, orphan, etc.]
- **Critical Risks**: [Top 3 feasibility risks]

## Go/No-Go Recommendation
[RECOMMEND PROCEED / RECOMMEND ADDITIONAL VALIDATION / DO NOT RECOMMEND]

Rationale: [2-3 sentence summary]

2. Disease Background

• Indication definition
• Prevalence and incidence (with sources)
• Current standard of care
• Unmet medical need
• Disease biology relevant to trial design

3. Patient Population Analysis

## 3.1 Base Population Size
- **US Incidence**: [X per 100,000] [★★☆: Source]
- **Prevalence**: [Y total patients in US] [★★★: CDC/NCI data]
- **Annual new cases**: [Z patients/year]

## 3.2 Biomarker Selection Impact
- **Biomarker**: [e.g., EGFR L858R mutation]
- **Prevalence in disease**: [%] [★★★: ClinVar/COSMIC]
- **Geographic variation**: [Asian vs. Caucasian, etc.]
- **Testing availability**: [FDA-approved tests, CLIA labs]

## 3.3 Eligibility Criteria Funnel
| Criterion | Remaining Patients | % Retained |
|-----------|-------------------|------------|
| Base disease population | [N] | 100% |
| Biomarker positive | [N × biomarker %] | [%] |
| Age 18-75 | [N × age factor] | [%] |
| No prior therapy | [N × treatment-naive %] | [%] |
| ECOG 0-1 | [N × performance factor] | [%] |
| Adequate organ function | [N × eligibility factor] | [%] |
| **FINAL ELIGIBLE POOL** | **[N]** | **[%]** |

## 3.4 Geographic Distribution
- High-incidence regions: [e.g., Asia 50%, US 15% for EGFR+]
- Trial site implications
- Recruitment strategy recommendations

## 3.5 Enrollment Projections
**Assumptions**:
- Eligible pool: [N patients/year in US]
- Site activation: [M sites]
- Screening success rate: [%]
- Patients per site per month: [X]

**Target Enrollment**: [Total N]
**Projected Timeline**: [Months]
**Sites Required**: [Minimum M sites]

4. Biomarker Strategy

## 4.1 Primary Biomarker
- **Biomarker**: [Gene mutation, protein expression, etc.]
- **Prevalence**: [%] [★★★: ClinVar data]
- **Assay Type**: [NGS, IHC, PCR, etc.]
- **FDA-Approved Tests**: [List CDx tests]
- **Turnaround Time**: [Days]
- **Cost**: [$X per test]

## 4.2 Alternative/Complementary Biomarkers
| Biomarker | Prevalence | Correlation | Testing |
|-----------|------------|-------------|---------|
| [Alt 1] | [%] | [R²] | [Method] |
| [Alt 2] | [%] | [R²] | [Method] |

## 4.3 Biomarker Testing Logistics
- Pre-screening vs. screening approach
- Central lab vs. local testing
- Tissue vs. liquid biopsy (ctDNA)
- Quality control requirements

5. Endpoint Selection & Justification

## 5.1 Primary Endpoint
**Proposed**: [e.g., Objective Response Rate (ORR)]

**Regulatory Precedent** [★★★]:
- [N] FDA approvals in [indication] using ORR (2015-2024)
- Recent example: [Drug] approved [Year] (ORR XX%, n=YY)
- Source: search_clinical_trials, FDA_get_approval_history

**Measurement Feasibility**:
- Assessment method: [RECIST 1.1, irRECIST, etc.]
- Imaging modality: [CT, MRI, PET]
- Assessment frequency: [Every X weeks]
- Independent review: [Yes/No, cost]

**Statistical Considerations**:
- Expected ORR: [%] (based on [source])
- Null hypothesis: [%]
- Sample size: [N] (α=0.05, β=0.20, two-sided)
- Response duration: [Median months]

## 5.2 Secondary Endpoints
| Endpoint | Evidence Grade | Feasibility | Rationale |
|----------|----------------|-------------|-----------|
| Progression-Free Survival (PFS) | ★★★ | High | FDA-accepted, precedent in [trials] |
| Duration of Response (DoR) | ★★☆ | High | Standard in oncology |
| Overall Survival (OS) | ★★★ | Low (early phase) | Follow-up for long-term |
| [Biomarker response] | ★☆☆ | Medium | Exploratory, mechanistic |

## 5.3 Exploratory Endpoints
- Pharmacodynamic biomarkers (proof-of-mechanism)
- ctDNA clearance (liquid biopsy)
- Quality of life (PRO-CTCAE)
- Correlative science (tumor profiling)

## 5.4 Endpoint Risks & Mitigation
- Risk: [Low response rate → sample size inflation]
- Mitigation: [Adaptive design, interim analysis]

6. Comparator Analysis

## 6.1 Standard of Care
**Current SOC**: [Drug name(s)]
- FDA approval: [Year] [★★★: FDA_OrangeBook]
- Efficacy: [ORR/PFS from pivotal trial]
- Limitations: [Resistance, toxicity, access]

**SOC Comparator Feasibility**: [HIGH/MEDIUM/LOW]

## 6.2 Trial Design Options
### Option A: Single-Arm vs. SOC
- **Design**: Phase 2, single-arm, N=[X]
- **Comparator**: Historical SOC data (ORR=[%])
- **Pros**: Faster enrollment, smaller N
- **Cons**: Selection bias, regulatory skepticism
- **Feasibility Score**: [0-100]

### Option B: Randomized vs. SOC
- **Design**: Phase 2, 1:1 randomization, N=[X] per arm
- **Comparator**: Active control ([SOC drug])
- **Pros**: Robust comparison, regulatory preferred
- **Cons**: 2x enrollment, comparator sourcing
- **Feasibility Score**: [0-100]

### Option C: Non-Inferiority Design
- **Rationale**: [If aiming for better safety with similar efficacy]
- **Non-inferiority margin**: [Δ = X%]
- **Sample size**: [N] (larger than superiority)

## 6.3 Comparator Drug Sourcing
- Commercial availability: [Yes/No]
- Patent status: [Generic available?]
- Cost: [$X per course]
- Stability and storage: [Requirements]

7. Safety Endpoints & Monitoring Plan

## 7.1 Primary Safety Endpoint
**Dose-Limiting Toxicity (DLT)** [for Phase 1 component]:
- DLT definition: [Grade 3+ non-hematologic, Grade 4+ hematologic]
- DLT assessment period: [Cycle 1, 28 days]
- Dose escalation rule: [3+3, BOIN, mTPI]

## 7.2 Mechanism-Based Toxicities
**Drug Class**: [Kinase inhibitor, checkpoint inhibitor, etc.]

**Expected Toxicities** [★★★: FAERS, label data]:
| Toxicity | Incidence | Grade 3+ | Monitoring |
|----------|-----------|----------|------------|
| Diarrhea | 60% | 10% | Symptom diary, hydration |
| Rash | 40% | 5% | Dermatology consult PRN |
| Hepatotoxicity | 20% | 3% | LFTs weekly (cycle 1), then q3w |
| [Specific AE] | [%] | [%] | [Plan] |

**Data Source**: FAERS_search_reports (similar drugs), drugbank_get_pharmacology

## 7.3 Organ-Specific Monitoring
```markdown
### Hepatic
- Baseline: LFTs, hepatitis panel
- Monitoring: AST/ALT/bili weekly (cycle 1), then q3w
- Stopping rule: ALT >5× ULN or bili >3× ULN

### Cardiac
- Baseline: ECG, ECHO if anthracycline history
- Monitoring: ECG q cycle, ECHO if symptoms
- Stopping rule: QTcF >500 ms, LVEF drop >15%

### Renal
- Baseline: Cr, eGFR, urinalysis
- Monitoring: Cr/eGFR q cycle
- Stopping rule: CrCl <30 mL/min

### [Organ X]
- [Similar structure]

7.4 Safety Monitoring Committee (SMC)

• Composition: [3 independent experts: oncologist, toxicologist, biostatistician]
• Review frequency: [After every 6 patients, then quarterly]
• Stopping rules: [≥3 DLTs at dose level, ≥2 drug-related deaths]

### 8. Study Design Recommendations
```markdown
## 8.1 Recommended Design
**Phase**: [1/2, 1b/2, 2]
**Design Type**: [Single-arm, randomized, basket, umbrella]
**Primary Objective**: [Assess safety and preliminary efficacy]

**Schema**:

[Indication + Biomarker] ↓ Screening (Biomarker testing) ↓ Enrollment ├─ [Phase 1 dose escalation: 3+3 design, N=12-18] │ Dose Levels: [X mg, Y mg, Z mg QD] │ DLT assessment: Cycle 1 (28 days) └─ [Phase 2 expansion: Simon 2-stage, N=43] Stage 1: N=13 (≥2 responses to proceed) Stage 2: N=30 additional Target ORR: 30% (H0: 10%, α=0.05, β=0.20)

## 8.2 Eligibility Criteria
**Inclusion**:
- Age ≥18 years
- Histologically confirmed [disease]
- [Biomarker] positive (central lab confirmed)
- Measurable disease per RECIST 1.1
- ECOG PS 0-1
- Adequate organ function
- [≤1 prior line for advanced disease]

**Exclusion**:
- Brain metastases (unless treated and stable)
- Prior [drug class] therapy
- Active infection, immunodeficiency
- Pregnancy/nursing
- Significant cardiovascular disease

## 8.3 Treatment Plan
- **Dosing**: [X mg PO QD, 28-day cycles]
- **Dose modifications**: [20% reductions for Grade 2+]
- **Duration**: Until progression, toxicity, or 24 months
- **Concomitant meds**: Supportive care allowed, restrictions on CYP3A4 inhibitors

## 8.4 Assessment Schedule
| Assessment | Screening | Cycle 1 | Cycles 2-6 | Cycles 7+ | EOT |
|------------|-----------|---------|------------|-----------|-----|
| History & PE | X | X | X | X | X |
| ECOG PS | X | X | X | X | X |
| Labs (CBC, CMP, LFT) | X | Weekly | q3w | q3w | X |
| Tumor imaging | X | - | q6w | q9w | X |
| ECG | X | - | q3w (if abnormal) | - | X |
| Biomarker (ctDNA) | X | C1D15 | q6w | - | X |
| AE assessment | - | Continuous | Continuous | Continuous | X |

9. Enrollment & Site Strategy

## 9.1 Site Selection Criteria
**Required Capabilities**:
- [Biomarker] testing (or central lab partnership)
- Phase 1/2 experience
- GCP compliance, IRB approval
- Access to [patient population]
- Investigator publications in [indication]

**Geographic Distribution**:
- US sites: [N] (target regions: [high-incidence areas])
- International: [Consider Asia if biomarker enriched there]

## 9.2 Enrollment Projections
**Assumptions**:
- Screening rate: [X patients/site/month]
- Screen failure rate: [30%] (biomarker negative, eligibility)
- Enrollment rate: [Y patients/site/month]

**Timeline** (N=[total]):
| Milestone | Month | Cumulative Enrolled |
|-----------|-------|---------------------|
| First site activated | 0 | 0 |
| First patient enrolled | 1 | 1 |
| 25% enrollment | [M1] | [0.25N] |
| 50% enrollment | [M2] | [0.5N] |
| 75% enrollment | [M3] | [0.75N] |
| Last patient enrolled | [M4] | [N] |
| Primary analysis | [M4 + follow-up] | - |

**Sites Required**: [Minimum M sites to achieve timeline]

## 9.3 Recruitment Strategies
- Physician outreach: Academic consortia, tumor boards
- Patient advocacy groups: [Organization names]
- ClinicalTrials.gov listing (prominent, lay summary)
- Social media: Targeted ads in [indication] communities
- Referral network: Community oncologists

10. Regulatory Pathway

## 10.1 FDA Pathway Selection
**Recommended**: [505(b)(1) / 505(b)(2) / Breakthrough / Orphan]

**Rationale**:
- [505(b)(1)]: New molecular entity, full development program
- [505(b)(2)]: [If relying on published safety data for similar drugs]
- **Breakthrough Therapy**: [If preliminary evidence of substantial improvement on serious outcome]
  - Criteria: [X-fold ORR vs. SOC in early data]
  - Benefits: Rolling review, frequent FDA meetings
- **Orphan Designation**: [If prevalence <200,000 in US]
  - Eligible if: [Biomarker-defined subtype constitutes orphan population]
  - Benefits: 7-year exclusivity, tax credits, fee waivers

## 10.2 Regulatory Precedents
**Similar Approvals** [★★★]:
- [Drug A]: [Indication], [Year], [Endpoint used], [N=X], [ORR=Y%]
- [Drug B]: [Indication], [Year], [Accelerated approval → full]
- Source: FDA_get_approval_history, drug labels

**FDA Guidance Documents**:
- [Relevant guidance title] (Year)
- Key recommendations: [e.g., ORR acceptable for Phase 2, confirmatory trial needed]

## 10.3 Pre-IND Meeting
**Recommended Topics**:
1. Primary endpoint acceptability (ORR vs. PFS)
2. Biomarker test qualification (CDx plan)
3. Comparator arm (single-arm acceptable?)
4. Pediatric study plan waiver
5. Safety monitoring plan

**Timing**: [3-4 months before IND submission]

## 10.4 IND Timeline
| Milestone | Month | Deliverable |
|-----------|-------|-------------|
| Pre-IND meeting request | -4 | Briefing package |
| Pre-IND meeting | -3 | FDA feedback |
| IND submission | 0 | Complete IND package |
| FDA 30-day review | 1 | Clinical hold or proceed |
| First patient dosed | 1-2 | After IND clearance |

11. Budget & Resource Considerations

## 11.1 Cost Drivers
| Item | Cost Estimate | Notes |
|------|---------------|-------|
| Protocol development | $50-100K | CRO or internal |
| IND preparation | $100-200K | CMC, toxicology reports |
| Site activation | $50K/site × [M sites] | IRB, contracts |
| Patient recruitment | $200-500K | Advertising, patient navigation |
| [Biomarker] testing | $[X]/patient | Central lab, CDx |
| Imaging (RECIST) | $3-5K/scan × [N scans] | CT, independent review |
| Drug supply | [Depends on sponsor] | If not sponsor-provided |
| CRO monitoring | $100-300/hour | Site visits, SDV |
| Data management | $150-300K | EDC, database lock |
| Statistical analysis | $50-100K | SAP, CSR |
| **TOTAL (Phase 1/2)** | **$[X-Y]M** | [N patients, M sites] |

## 11.2 Timeline & FTE Requirements
**Duration**: [X months] (enrollment) + [Y months] (follow-up)
**Team**:
- Medical monitor: 0.5 FTE
- Project manager: 0.8 FTE
- Clinical operations: 0.3 FTE
- Data manager: 0.3 FTE
- Biostatistician: 0.2 FTE

12. Risk Assessment

## 12.1 Feasibility Risks (High Priority)
| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Slow enrollment (biomarker screen fail) | HIGH | HIGH | - Expand sites to [high-prevalence regions]<br>- Allow alternative biomarkers<br>- Liquid biopsy screening |
| Low response rate (ORR <10%) | MEDIUM | CRITICAL | - Interim futility analysis (Simon stage 1)<br>- Lower null hypothesis if justified<br>- Pivot to combination if single-agent weak |
| Unexpected toxicity (>33% DLT rate) | LOW | CRITICAL | - Conservative starting dose (50% MTD from preclin)<br>- Dose escalation with BOIN (adaptive)<br>- Close SMC oversight |
| Comparator drug supply issues | MEDIUM | MEDIUM | - Secure commercial supply early<br>- Generic sourcing if available |
| Regulatory pushback on single-arm design | MEDIUM | HIGH | - Pre-IND meeting to align<br>- Plan for randomized Phase 2b if needed |

## 12.2 Scientific Risks
- Biomarker hypothesis unvalidated: [Correlative studies to de-risk]
- Patient heterogeneity: [Stratification by [factor]]
- Resistance mechanisms: [Serial biopsies for molecular profiling]

13. Success Criteria & Go/No-Go Decision

## 13.1 Phase 1 Success Criteria (Go to Phase 2)
- [ ] ≤33% DLT rate at RP2D
- [ ] ≥50% patients achieve [PD biomarker response]
- [ ] No unexpected safety signals (Grade 5 AEs, new class effects)
- [ ] PK supports QD dosing

## 13.2 Phase 2 Interim Analysis (Simon Stage 1)
- **Enrollment**: 13 patients
- **Decision Rule**:
  - ≥2 responses (ORR ≥15%) → Proceed to Stage 2
  - <2 responses → Stop for futility

## 13.3 Phase 2 Final Success Criteria (Advance to Phase 3)
- [ ] ORR ≥30% (95% CI lower bound >10%)
- [ ] Median DoR ≥6 months
- [ ] PFS signal (HR <0.7 vs. historical SOC)
- [ ] Safety profile manageable (Grade ≥3 AE <40%)
- [ ] Biomarker correlation with response (enrichment signal)

## 13.4 Feasibility Scorecard
| Dimension | Weight | Score (0-10) | Weighted | Grade |
|-----------|--------|--------------|----------|-------|
| **Patient Availability** | 30% | [X] | [0.30×X] | [★★☆] |
| - Base population size | - | [X] | - | [Source] |
| - Biomarker prevalence | - | [X] | - | [ClinVar data] |
| - Site access | - | [X] | - | [N sites feasible] |
| **Endpoint Precedent** | 25% | [X] | [0.25×X] | [★★★] |
| - Regulatory acceptance | - | [X] | - | [FDA approvals using ORR] |
| - Measurement feasibility | - | [X] | - | [RECIST standard] |
| **Regulatory Clarity** | 20% | [X] | [0.20×X] | [★★☆] |
| - Pathway defined | - | [X] | - | [Breakthrough potential] |
| - Precedent approvals | - | [X] | - | [Similar indications] |
| **Comparator Feasibility** | 15% | [X] | [0.15×X] | [★★★] |
| - SOC availability | - | [X] | - | [FDA-approved, generic] |
| - Historical data | - | [X] | - | [Published ORR: X%] |
| **Safety Monitoring** | 10% | [X] | [0.10×X] | [★★☆] |
| - Known toxicities | - | [X] | - | [FAERS, class effects] |
| - Monitoring plan | - | [X] | - | [Defined, feasible] |
| **TOTAL FEASIBILITY SCORE** | **100%** | - | **[XX/100]** | - |

**Interpretation**:
- **≥75**: HIGH feasibility - Recommend proceed to protocol development
- **50-74**: MODERATE feasibility - Additional validation recommended
- **<50**: LOW feasibility - Significant de-risking required

14. Recommendations & Next Steps

## 14.1 Final Recommendation
**GO / CONDITIONAL GO / NO-GO**: [Decision]

**Rationale**:
[2-3 paragraphs synthesizing feasibility analysis. Example:]

This trial demonstrates HIGH feasibility (score: 82/100) for the following reasons:
1. **Patient availability is strong** (★★★): EGFR+ NSCLC affects ~18,000 US patients/year,
   with L858R representing 45% (8,100 patients). With 20 sites, enrollment of N=43 is
   achievable in 8-10 months.
2. **Endpoint precedent is robust** (★★★): ORR is FDA-accepted for accelerated approval
   in NSCLC (18 precedents since 2015). RECIST 1.1 is standard, feasible.
3. **Regulatory pathway is clear** (★★☆): 505(b)(1) with breakthrough therapy potential
   given 2x ORR improvement vs. SOC. Pre-IND meeting advised to confirm single-arm design.

**Key Risk**: Enrollment may slow if sites lack rapid EGFR testing. Mitigation: Central
liquid biopsy with 7-day turnaround.

## 14.2 Critical Path to IND
**Immediate Next Steps** (Months 0-3):
- [ ] Request pre-IND meeting with FDA (target Month 1)
- [ ] Initiate CDx partnership for [biomarker] test (FDA clearance path)
- [ ] Secure drug supply (GMP manufacturing, stability)
- [ ] Draft protocol (v1.0) and ICF
- [ ] Site feasibility surveys (target [M] sites)

**IND Preparation** (Months 3-6):
- [ ] Complete CMC section (drug substance/product, manufacturing)
- [ ] Finalize preclinical package (toxicology, pharmacology)
- [ ] Prepare clinical protocol (incorporate FDA feedback)
- [ ] Develop CRFs and EDC database
- [ ] IND submission (Month 6)

**Post-IND** (Months 6-9):
- [ ] IRB submissions (central IRB for multi-site)
- [ ] Site contracts and budgets
- [ ] Investigator meeting
- [ ] First patient enrolled (Month 7-8)

## 14.3 Alternative Designs (If Current Design Infeasible)
**Plan B**: [If enrollment too slow]
- Broaden biomarker criteria (e.g., all EGFR mutations, not just L858R)
- Add international sites (Asia, EU)
- Basket design (multiple cancers with EGFR mutations)

**Plan C**: [If single-arm rejected by FDA]
- Randomized Phase 2 (1:1 vs. SOC)
- Increase sample size to N=86 (43/arm)
- Requires 2x sites and budget

## 14.4 Long-Term Development Strategy
**If Phase 2 Successful**:
- Phase 3 design: Randomized, OS primary endpoint, N=300-500
- Companion diagnostic (CDx): Parallel FDA submission
- Commercial readiness: Manufacturing scale-up
- Patent strategy: File composition-of-matter or method-of-use

**Market Considerations**:
- Addressable market: [8,100 EGFR L858R NSCLC patients/year in US]
- Competitive landscape: [Osimertinib, other EGFR TKIs]
- Differentiation: [e.g., Activity against T790M resistance]
- Pricing: [$10-15K/month based on comparators]

Complete Example Workflow

Example: EGFR L858R+ NSCLC Phase 1/2 Trial

from tooluniverse import ToolUniverse

tu = ToolUniverse(use_cache=True)
tu.load_tools()

# ============================================================================
# PATH 1: PATIENT POPULATION SIZING
# ============================================================================

# Step 1.1: Get disease prevalence
disease_info = tu.tools.OpenTargets_get_disease_id_description_by_name(
    diseaseName="non-small cell lung cancer"
)
efo_id = disease_info['data']['id']

# Get phenotype data (includes prevalence if available)
phenotypes = tu.tools.OpenTargets_get_diseases_phenotypes(
    efoId=efo_id
)
# Note: May need to supplement with literature (PubMed) for specific prevalence

# Step 1.2: Estimate EGFR mutation prevalence
egfr_variants = tu.tools.ClinVar_search_variants(
    gene="EGFR",
    significance="pathogenic,likely_pathogenic"
)

# Filter to L858R specifically
l858r_variants = [v for v in egfr_variants['data']
                  if 'L858R' in v.get('name', '')]

# Also check population databases for allele frequency
gnomad_egfr = tu.tools.gnomAD_search_gene_variants(
    gene="EGFR"
)
# Filter to L858R and sum allele frequencies

# Step 1.3: Search literature for epidemiology
epi_papers = tu.tools.PubMed_search_articles(
    query="EGFR L858R prevalence non-small cell lung cancer epidemiology",
    max_results=20
)
# Extract prevalence estimates from recent papers

# ============================================================================
# PATH 2: BIOMARKER PREVALENCE & TESTING
# ============================================================================

# Step 2.1: Find FDA-approved CDx tests
# Search FDA device database (via PubMed or manual lookup)
cdx_search = tu.tools.PubMed_search_articles(
    query="FDA approved companion diagnostic EGFR L858R",
    max_results=10
)

# Step 2.2: Literature on EGFR testing in clinical practice
testing_papers = tu.tools.PubMed_search_articles(
    query="EGFR mutation testing guidelines NCCN turnaround time",
    max_results=15
)

# ============================================================================
# PATH 3: COMPARATOR SELECTION
# ============================================================================

# Step 3.1: Find current standard of care (osimertinib)
soc_drug = "osimertinib"

soc_info = tu.tools.drugbank_get_drug_basic_info_by_drug_name_or_id(
    drug_name_or_drugbank_id=soc_drug
)

soc_indications = tu.tools.drugbank_get_indications_by_drug_name_or_drugbank_id(
    drug_name_or_drugbank_id=soc_drug
)

soc_pharmacology = tu.tools.drugbank_get_pharmacology_by_drug_name_or_drugbank_id(
    drug_name_or_drugbank_id=soc_drug
)

# Step 3.2: Check FDA Orange Book for approved generics
orange_book = tu.tools.FDA_OrangeBook_search_drugs(
    ingredient=soc_drug
)

# Step 3.3: Find FDA approval details
fda_approval = tu.tools.FDA_get_drug_approval_history(
    drug_name=soc_drug
)

# ============================================================================
# PATH 4: ENDPOINT SELECTION
# ============================================================================

# Step 4.1: Search for precedent Phase 2 trials in EGFR+ NSCLC
precedent_trials = tu.tools.search_clinical_trials(
    condition="EGFR positive non-small cell lung cancer",
    phase="2",
    status="completed"
)

# Analyze which primary endpoints were used (ORR, PFS, etc.)
orr_trials = [t for t in precedent_trials['data']
              if 'response rate' in t.get('primary_outcome', '').lower()]

# Step 4.2: Find FDA approvals using ORR as primary endpoint
orr_approvals = tu.tools.PubMed_search_articles(
    query="FDA approval objective response rate NSCLC accelerated approval",
    max_results=30
)

# Step 4.3: Get detailed trial results for sample size justification
# Use ClinicalTrials.gov NCT number from precedent_trials
for trial in precedent_trials['data'][:5]:
    nct_id = trial.get('nct_number')
    trial_details = tu.tools.search_clinical_trials(
        nct_id=nct_id
    )
    # Extract: ORR, n, confidence intervals

# ============================================================================
# PATH 5: SAFETY ENDPOINTS & MONITORING
# ============================================================================

# Step 5.1: Get mechanism-based toxicity from drug class
# If testing an EGFR inhibitor, search for class effects
class_drug = "erlotinib"  # Example EGFR TKI for class effect reference

class_safety = tu.tools.drugbank_get_pharmacology_by_drug_name_or_drugbank_id(
    drug_name_or_drugbank_id=class_drug
)

class_warnings = tu.tools.FDA_get_warnings_and_cautions_by_drug_name(
    drug_name=class_drug
)

# Step 5.2: FAERS data for real-world adverse events
faers_egfr_tki = tu.tools.FAERS_search_reports_by_drug_and_reaction(
    drug_name="erlotinib",
    limit=500
)

# Summarize top adverse events
ae_summary = tu.tools.FAERS_count_reactions_by_drug_event(
    medicinalproduct="ERLOTINIB"
)

# Step 5.3: Search for DLT definitions in similar trials
dlt_papers = tu.tools.PubMed_search_articles(
    query="dose limiting toxicity Phase 1 EGFR inhibitor definition",
    max_results=20
)

# ============================================================================
# PATH 6: REGULATORY PATHWAY
# ============================================================================

# Step 6.1: Search for breakthrough therapy designations in NSCLC
breakthrough_search = tu.tools.PubMed_search_articles(
    query="FDA breakthrough therapy designation NSCLC EGFR mutation",
    max_results=20
)

# Step 6.2: Check if indication qualifies for orphan drug status
# L858R is subset of NSCLC; estimate US prevalence
us_nsclc_annual = 200000  # From epidemiology data
l858r_prevalence = 0.45 * 0.15  # 45% of EGFR+ (15% of NSCLC)
l858r_annual_us = us_nsclc_annual * l858r_prevalence  # ~13,500/year
# Note: Orphan requires <200,000 total prevalence; may not qualify if prevalent

# Step 6.3: Find relevant FDA guidance documents
fda_guidance_search = tu.tools.PubMed_search_articles(
    query="FDA guidance clinical trial endpoints oncology non-small cell lung cancer",
    max_results=15
)

# ============================================================================
# COMPILE FEASIBILITY REPORT
# ============================================================================

# Now compile all data into the 14-section report structure
# Calculate feasibility score based on findings

feasibility_scores = {
    'patient_availability': 8,  # 8/10 based on 13,500 patients/year, good access
    'endpoint_precedent': 9,    # 9/10 ORR widely accepted
    'regulatory_clarity': 7,    # 7/10 breakthrough possible, single-arm needs FDA input
    'comparator_feasibility': 9, # 9/10 osimertinib available, efficacy data clear
    'safety_monitoring': 8      # 8/10 EGFR TKI class effects well-characterized
}

weights = {
    'patient_availability': 0.30,
    'endpoint_precedent': 0.25,
    'regulatory_clarity': 0.20,
    'comparator_feasibility': 0.15,
    'safety_monitoring': 0.10
}

overall_score = sum(feasibility_scores[k] * weights[k] * 10 for k in weights.keys())
# overall_score = 81/100 → HIGH feasibility

print(f"Feasibility Score: {overall_score}/100 - HIGH")
print("Recommendation: RECOMMEND PROCEED to protocol development")

Tool Reference by Research Path

PATH 1: Patient Population Sizing

• OpenTargets_get_disease_id_description_by_name - Disease lookup
• OpenTargets_get_diseases_phenotypes - Prevalence data
• ClinVar_search_variants - Biomarker mutation frequency
• gnomAD_search_gene_variants - Population allele frequencies
• PubMed_search_articles - Epidemiology literature
• search_clinical_trials - Enrollment feasibility from past trials

PATH 2: Biomarker Prevalence & Testing

• ClinVar_get_variant_details - Variant pathogenicity
• COSMIC_search_mutations - Cancer-specific mutation frequencies
• gnomAD_get_variant_details - Population genetics
• PubMed_search_articles - CDx test performance, guidelines

PATH 3: Comparator Selection

• drugbank_get_drug_basic_info_by_drug_name_or_id - Drug info
• drugbank_get_indications_by_drug_name_or_drugbank_id - Approved indications
• drugbank_get_pharmacology_by_drug_name_or_drugbank_id - Mechanism
• FDA_OrangeBook_search_drugs - Generic availability
• FDA_get_drug_approval_history - Approval details
• search_clinical_trials - Historical control data

PATH 4: Endpoint Selection

• search_clinical_trials - Precedent trials, endpoints used
• PubMed_search_articles - FDA acceptance history, endpoint validation
• FDA_get_drug_approval_history - Approved endpoints by indication

PATH 5: Safety Endpoints & Monitoring

• drugbank_get_pharmacology_by_drug_name_or_drugbank_id - Mechanism toxicity
• FDA_get_warnings_and_cautions_by_drug_name - FDA black box warnings
• FAERS_search_reports_by_drug_and_reaction - Real-world adverse events
• FAERS_count_reactions_by_drug_event - AE frequency
• FAERS_count_death_related_by_drug - Serious outcomes
• PubMed_search_articles - DLT definitions, monitoring strategies

PATH 6: Regulatory Pathway

• FDA_get_drug_approval_history - Precedent approvals
• PubMed_search_articles - Breakthrough designations, FDA guidance
• search_clinical_trials - Regulatory precedents (accelerated approval)

Best Practices

1. Start with Report Template

Create full report structure FIRST, then populate:

# Clinical Trial Feasibility Report: [INDICATION]
## 1. Executive Summary
[Researching...]
## 2. Disease Background
[Researching...]
[...all 14 sections...]

2. Use English for All Tool Calls

Even if user asks in another language:

• "EGFR+ NSCLC" not "EGFR+ 非小细胞肺癌"
• "breast cancer" not "cancer du sein"
• Translate results back to user's language

3. Validate Biomarker Prevalence Across Sources

Cross-check ClinVar, gnomAD, COSMIC, and literature:

• ClinVar: Clinical significance
• gnomAD: Population frequency (for germline)
• COSMIC: Somatic mutation frequency in cancers
• Literature: Geographic/ethnic variation

4. Calculate Enrollment Funnel Explicitly

Show math for patient availability:

US NSCLC incidence: 200,000/year
× EGFR+ prevalence: 15% = 30,000
× L858R within EGFR+: 45% = 13,500
× Eligible (age, PS, prior Tx): 60% = 8,100
÷ Competing trials: 3 = 2,700 available/year

For N=43, need 43/2,700 = 1.6% capture rate → Achievable

5. Evidence Grade Every Key Claim

EGFR L858R prevalence is 45% of EGFR+ NSCLC [★★★: PMID:12345, large
sequencing study n=1,500]. *Source: ClinVar, COSMIC*

6. Provide Regulatory Precedent Details

Not just "ORR is accepted" but:

ORR is FDA-accepted for accelerated approval in NSCLC [★★★: FDA approvals]:
- Osimertinib (2015): ORR 57%, n=411, Tx-resistant EGFR+ (NCT01802632)
- Dacomitinib (2018): ORR 45%, n=452, 1L EGFR+ (NCT01774721)
- [3 more examples]

7. Address Feasibility Risks Proactively

For each HIGH risk, provide mitigation:

Risk: Biomarker screen failure rate >70%
→ Mitigation: Liquid biopsy pre-screening (ctDNA EGFR, 7-day turnaround)

8. Separate Phase 1 and Phase 2 Components

If combined Phase 1/2:

• Phase 1: Safety, DLT, RP2D (N=12-18, 3+3 or BOIN)
• Phase 2: Efficacy, ORR (N=43, Simon 2-stage)
• Distinct success criteria for each phase

Common Pitfalls to Avoid

❌ Don't: Show Tool Outputs to User

# BAD
OpenTargets returned:
{
  "data": {
    "id": "EFO_0003060",
    "name": "non-small cell lung carcinoma"
  }
}

✅ Do: Present Synthesized Report

# GOOD
## Disease Background
Non-small cell lung cancer (NSCLC) represents 85% of lung cancers, with
~200,000 new cases annually in the US [★★★: CDC WONDER]. EGFR mutations
occur in 15% of Caucasian and 50% of Asian patients [★★★: PMID:23816960].
*Source: OpenTargets, ClinVar*

❌ Don't: Make Unsupported Claims

# BAD
ORR of 60% is expected based on preclinical data.

✅ Do: Ground in Evidence

# GOOD
ORR of 30-40% is projected [★★☆] based on:
- Similar EGFR TKI (erlotinib): 32% ORR in EGFR+ NSCLC (NCT00949650)
- Our drug's 2× IC50 potency vs. erlotinib (preclinical)
*Source: ClinicalTrials.gov, internal data*

❌ Don't: Ignore Geographic Variation

# BAD
EGFR L858R prevalence: 7% of NSCLC

✅ Do: Specify Geography

# GOOD
EGFR L858R prevalence [★★★: COSMIC, ClinVar]:
- Caucasian (US/EU): 6-7% of NSCLC
- East Asian: 20-25% of NSCLC
→ Trial site strategy: Include Asian sites for 2× enrollment

Output Format Requirements

Report File Naming

• [INDICATION]_trial_feasibility_report.md
• Example: EGFR_L858R_NSCLC_trial_feasibility_report.md

Section Completeness

All 14 sections MUST be present:

1. Executive Summary
2. Disease Background
3. Patient Population Analysis (with funnel)
4. Biomarker Strategy
5. Endpoint Selection & Justification
6. Comparator Analysis
7. Safety Endpoints & Monitoring Plan
8. Study Design Recommendations
9. Enrollment & Site Strategy
10. Regulatory Pathway
11. Budget & Resource Considerations
12. Risk Assessment
13. Success Criteria & Go/No-Go Decision (with scorecard)
14. Recommendations & Next Steps

Evidence Grading Required In

• Section 1 (Executive Summary): Key findings
• Section 4 (Biomarker): Prevalence claims
• Section 5 (Endpoints): Regulatory precedents
• Section 6 (Comparator): SOC efficacy data
• Section 7 (Safety): Toxicity frequencies
• Section 10 (Regulatory): Approval precedents
• Section 13 (Scorecard): All dimensions

Feasibility Score Transparency

Show calculation:

| Dimension | Weight | Raw Score | Weighted | Evidence |
|-----------|--------|-----------|----------|----------|
| Patient Availability | 30% | 8/10 | 24 | ★★★: Epi data |
| Endpoint Precedent | 25% | 9/10 | 22.5 | ★★★: FDA approvals |
| Regulatory Clarity | 20% | 7/10 | 14 | ★★☆: Pre-IND advised |
| Comparator Feasibility | 15% | 9/10 | 13.5 | ★★★: Generic avail |
| Safety Monitoring | 10% | 8/10 | 8 | ★★☆: Class effects |
| **TOTAL** | **100%** | - | **82/100** | **HIGH** |

Example Use Cases

Use Case 1: Biomarker-Selected Oncology Trial

Query: "Assess feasibility of Phase 2 trial for EGFR L858R+ NSCLC, ORR primary endpoint"

Workflow:

1. Disease prevalence: 200K NSCLC/year × 15% EGFR+ = 30K
2. Biomarker: L858R is 45% of EGFR+ → 13.5K/year
3. Eligible: 60% → 8K/year
4. Endpoint: ORR accepted (osimertinib precedent)
5. Comparator: Osimertinib (ORR 57%, generic available)
6. Feasibility: HIGH (82/100) → RECOMMEND PROCEED

Use Case 2: Rare Disease Trial

Query: "Feasibility of trial in Niemann-Pick Type C (prevalence 1:120,000)"

Workflow:

1. US prevalence: ~2,750 patients total, ~25 new cases/year
2. Endpoint challenge: No validated clinical outcome
3. Orphan drug: QUALIFIED (7-year exclusivity)
4. Comparator: No approved drugs → single-arm feasible
5. Enrollment: Multi-year, need ALL US centers
6. Feasibility: MODERATE (58/100) → CONDITIONAL GO (requires patient registry partnership)

Use Case 3: Superiority Trial vs. Standard of Care

Query: "Phase 2b design for new checkpoint inhibitor vs. pembrolizumab in PD-L1 high NSCLC"

Workflow:

1. Patient availability: 40K PD-L1 high NSCLC/year (HIGH)
2. Endpoint: ORR for Phase 2b, plan OS for Phase 3
3. Comparator: Pembrolizumab (ORR 45%, PFS 10mo) - readily available
4. Design: Randomized 1:1, N=120 (60/arm) for 20% ORR improvement
5. Feasibility: HIGH (78/100) → RECOMMEND PROCEED

Use Case 4: Non-Inferiority Trial

Query: "Non-inferiority trial for oral anticoagulant vs. warfarin"

Workflow:

1. Patient availability: 2M AFib patients, 600K on warfarin (HIGH)
2. Endpoint: Stroke/SE (FDA-accepted, but requires large N)
3. Non-inferiority margin: HR <1.5 (FDA guidance)
4. Sample size: N=5,000+ for 90% power → LARGE trial
5. Comparator: Warfarin generic, INR monitoring standard
6. Feasibility: MODERATE (65/100) - large N drives cost and timeline

Use Case 5: Basket Trial (Multiple Cancers, One Biomarker)

Query: "Basket trial for NTRK fusion+ solid tumors (15 histologies)"

Workflow:

1. Patient availability: NTRK fusions rare (<1% across cancers) → Broad screening
2. Biomarker testing: NGS required (FDA-approved FoundationOne CDx)
3. Endpoint: ORR (precedent: larotrectinib approval, ORR 75%, n=55)
4. Design: Single-arm, N=15-20 per histology × 5-10 histologies
5. Regulatory: Tissue-agnostic approval precedent (★★★: pembrolizumab MSI-H)
6. Feasibility: MODERATE (62/100) - enrollment slow but feasible with broad screening

Integration with Other Skills

Works Well With

• tooluniverse-drug-research: Investigate mechanism, preclinical data
• tooluniverse-disease-research: Deep dive on disease biology
• tooluniverse-target-research: Validate drug target, essentiality
• tooluniverse-pharmacovigilance: Post-market safety for comparator drugs
• tooluniverse-precision-oncology: Biomarker biology, resistance mechanisms

Complementary Analyses

After feasibility report, consider:

1. Budget model: Use cost estimates to build financial model
2. Site feasibility surveys: Validate enrollment projections with sites
3. Regulatory strategy document: Detailed FDA interaction plan
4. Statistical analysis plan (SAP): Translate design into statistical methods

Version Information

• Version: 1.0.0
• Last Updated: February 2026
• Compatible with: ToolUniverse 0.5+
• Focus: Phase 1/2 early clinical development

Support & Resources

• ToolUniverse Docs: https://zitniklab.hms.harvard.edu/ToolUniverse/
• FDA Guidance Documents: https://www.fda.gov/regulatory-information/search-fda-guidance-documents
• ClinicalTrials.gov: https://clinicaltrials.gov/
• Slack Community: https://join.slack.com/t/tooluniversehq/shared_invite/zt-3dic3eoio-5xxoJch7TLNibNQn5_AREQ